ArticleFrontiers in immunology2026
Case Report: A rare case of IgG4-related disease initially manifesting with diarrhea and jaundice.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: IgG4-related disease (IgG4-RD) is a systemic immune-mediated fibrosing inflammatory disorder with multi-organ involvement. Due to highly variable and nonspecific clinical manifestations, atypical cases are prone to misdiagnosis and missed diagnosis. This study reports an IgG4-RD case presenting with rare initial symptoms of diarrhea and jaundice, aiming to enrich the clinical spectrum of atypical IgG4-RD and improve early differential diagnosis. Case presentation: A 62-year-old male with well-controlled type 2 diabetes mellitus presented with 10 days of refractory mucoid diarrhea with occasional hematochezia and 2 days of progressive obstructive jaundice, pale stool, and generalized pruritus, accompanied by a 25 kg unintentional weight loss within one year. Laboratory tests showed markedly elevated transaminases, bilirubin, bile acid, alkaline phosphatase, gamma-glutamyl transpeptidase, CA19-9, erythrocyte sedimentation rate, and serum IgG4. Imaging revealed extrahepatic bile duct wall thickening and stenosis, sausage-like pancreatic swelling, and multi-organ lesions involving the bilateral renal hilum and retroperitoneum. Since pathological biopsy was declined by the patient and his family, a clinical suspicion of IgG4-related sclerosing cholangitis was established based on consistent clinical, serological, and typical multi-organ imaging features, although histopathology remains the gold standard for definitive diagnosis. The patient received liver-protective, glucocorticoid anti-inflammatory, nutritional, and anti-osteoporosis treatments. His symptoms resolved rapidly with significantly improved liver function, and he was discharged in stable condition. Ten-month regular follow-up was completed after discharge; no disease recurrence or adverse reactions were observed during gradual steroid tapering and maintenance phase. Conclusion: IgG4-RD with initial diarrhea and jaundice is easily misdiagnosed as cholangiocarcinoma or primary sclerosing cholangitis. Markedly elevated serum IgG4 combined with characteristic multi-organ imaging changes can strongly support a clinical suspicion of IgG4-RD, but cannot independently establish a definitive diagnosis without histopathological evidence. The gold-standard definite diagnosis requires integrated fulfillment of clinical, serological, radiological and pathological criteria. Glucocorticoid therapy is effective for symptom relief and biochemical improvement in suspected cases. The patient maintained sustained remission during the 10-month follow-up without relapse, demonstrating favorable medium-term prognosis, while long-term serial monitoring is still essential to further reduce late recurrence risk and optimize long-term prognosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.